Fluconazole resistance in cryptococcal disease: emerging or intrinsic?

References

• Perfect JR, Dismukes WE, Dromer F, . Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50: 291–322.
   PubMed Web of Science ®Google Scholar
• Bicanic T, Wood R, Bekker LG, . Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. Lancet Infect Dis 2005; 5: 530–531.
   PubMed Web of Science ®Google Scholar
• Wertheimer AI, Santella TM, Lauver HJ. Successful public/private donation programs: a review of the Diflucan Partnership Program in South Africa. J Int Assoc Physicians AIDS Care (Chic) 2004; 3: 74–79, 84–85.
   PubMedGoogle Scholar
• Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS – 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8: 515–548.
   PubMed Web of Science ®Google Scholar
• Bii CC, Makimura K, Abe S, . Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya. Mycoses 2007; 50: 25–30.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL, . Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2009; 47: 117–123.
   PubMed Web of Science ®Google Scholar
• Brandt ME, Pfaller MA, Hajjeh RA, . Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 2001; 45: 3065–3069.
   PubMedGoogle Scholar
• Govender NP, Patel J, van Wyk M, Chiller TM, Lockhart SR. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002–2003 and C2007–2008. Antimicrob Agents Chemother 2011; 55: 2606–2611.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, approved standard, M27-A3, 3rd ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
   Google Scholar
• Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibilty Testing (EUCAST). EUCAST definitive document EDef 7.1: Method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008;14: 398–405.
   PubMedGoogle Scholar
• European Committee for Antimicrobial Susceptibility Testing. Consultation on EUCAST Definitive Document Edef 7.2: Method for determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. European Society of Clinical Microbiology and Infectious Diseases, 2012.
   Google Scholar
• Zaragoza O, Mesa-Arango AC, Gomez-Lopez A, . Process analysis of variables for standardization of antifungal susceptibility testing of nonfermentative yeasts. Antimicrob Agents Chemother 2011; 55: 1563–1570.
   Google Scholar
• Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagn Microbiol Infect Dis 2011; 71: 252–259.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Method for Antifungal Disk Diffusion Susceptibility Testing in Yeasts. Approved guideline, M44-A, Wayne, PA: Clinical and Laboratory Standards Institute, 2002.
   Google Scholar
• Borghi E, Iatta R, Sciota R, . Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study. J Clinical Microbiol 2010; 48: 3153–3157.
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA, Walsh TJ, . Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14: 643–658.
   PubMed Web of Science ®Google Scholar
• Chen SC, O’Donnell ML, Gordon S, Gilbert GL. Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique. J Antimicrob Chemother 1996; 37: 265–273.
   PubMed Web of Science ®Google Scholar
• Arikan S, Gur D, Akova M. Comparison of Etest, microdilution and colorimetric dilution with reference broth macrodilution method for antifungal susceptibility testing of clinically significant Candida species isolated from immunocompromised patients. Mycoses 1997; 40: 291–296.
   PubMed Web of Science ®Google Scholar
• Barry AL, Pfaller MA, Brown SD, . Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol 2000; 38: 3457–3459.
   PubMed Web of Science ®Google Scholar
• Davey KG, Johnson EM, Holmes AD, Szekely A, Warnock DW. In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole. J Antimicrob Chemother 1998; 42: 217–220.
   PubMed Web of Science ®Google Scholar
• Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ. Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob Agents Chemother 2009; 53: 2804–2815.
   Google Scholar
• Varma A, Kwon-Chung KJ. Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob Agents Chemother 2010; 54: 2303–2311.
   PubMed Web of Science ®Google Scholar
• Mondon P, Petter R, Amalfitano G, . Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother 1999; 43: 1856–1861.
   PubMed Web of Science ®Google Scholar
• Coker RJ, Harris JR. Failure of fluconazole treatment in cryptococcal meningitis despite adequate CSF levels. J Infect 1991; 23: 101–103.
   Google Scholar
• Peetermans W, Bobbaers H, Verhaegen J, Vandepitte J. Fluconazole-resistant Cryptococcus neoformans var gattii in an AIDS patient. Acta Clin Belg 1993; 48: 405–409.
   PubMed Web of Science ®Google Scholar
• Orni-Wasserlauf R, Izkhakov E, Siegman-Igra Y, . Fluconazole-resistant Cryptococcus neoformans isolated from an immunocompetent patient without prior exposure to fluconazole. Clin Infect Dis 1999; 29: 1592–1593.
   PubMed Web of Science ®Google Scholar
• Soares BM, Santos DA, Kohler LM, . Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing. Rev Iberoam Micol 2008;31; 25: 242–245.
   Google Scholar
• Viard JP, Hennequin C, Fortineau N, . Fulminant cryptococcal infections in HIV-infected patients on oral fluconazole. Lancet 1995; 346: 118.
   Google Scholar
• Berg J, Clancy CJ, Nguyen MH. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis 1998; 26: 186–187.
   PubMed Web of Science ®Google Scholar
• Paugam A, Dupouy-Camet J, Blanche P, . Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis 1994; 19: 975–976.
   PubMedGoogle Scholar
• Birley HD, Johnson EM, McDonald P, . Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int J STD AIDS 1995; 6: 353–355.
   PubMedGoogle Scholar
• Armengou A, Porcar C, Mascaro J, Garcia-Bragado F. Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996; 23: 1337–1338.
   PubMedGoogle Scholar
• Friese G, Discher T, Fussle R, Schmalreck A, Lohmeyer J. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS 2001; 15: 2344–2345.
   PubMed Web of Science ®Google Scholar
• Rodero L, Mellado E, Rodriguez AC, . G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother 2003; 47: 3653–3656.
   PubMed Web of Science ®Google Scholar
• Assing K, Birgens H, Arendrup M. Cryptococcus neoformans var neoformans resistant to fluconazole in an HIV-negative patient with chronic lymphocytic leukemia. Clin Microbiol Infect 2003; 9: 441–444.
   PubMed Web of Science ®Google Scholar
• Momoff N, Parrish A. Fluconazole-resistant cryptococcal meningitis. South African Med J [Suid-Afrikaanse Tydskrif vir Geneeskunde] 2003; 93: 444.
   Google Scholar
• Chang HH, Lee NY, Ko WC, . Voriconazole inhibition of tacrolimus metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis. Int J Infect Dis 2010; 14: 348–350.
   PubMed Web of Science ®Google Scholar
• Aller AI, Martin-Mazuelos E, Lozano F, . Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000; 44: 1544–1548.
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Abdul M, Arpin M, . Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006; 50: 2464–2470.
   PubMed Web of Science ®Google Scholar
• Jessup CJ, Pfaller MA, Messer SA, . Fluconazole susceptibility testing of Cryptococcus neoformans: comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients. J Clin Microbiol 1998; 36: 2874–2876.
   PubMedGoogle Scholar
• Witt MD, Lewis RJ, Larsen RA, . Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing. Clin Infect Dis 1996; 22: 322–328.
   PubMed Web of Science ®Google Scholar
• Brandt ME, Pfaller MA, Hajjeh RA, . Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated cryptococcosis. Cryptococcal Disease Active Surveillance Group. J Infect Dis 1996; 174: 812–820.
   PubMed Web of Science ®Google Scholar
• Sar B, Monchy D, Vann M, . Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 2004; 54: 563–565.
   PubMed Web of Science ®Google Scholar
• Hamill RJ. Free fluconazole for cryptococcal meningitis: too little of a good thing? Clin Infect Dis 2006; 43: 1074–1076.
   Google Scholar
• Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006; 43: 1069–1073.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard NCCLS document M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
   Google Scholar
• Chandenier J, Adou-Bryn KD, Douchet C, . In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia. Eur J Clin Microbiol Infect Dis 2004; 23: 506–508.
   PubMed Web of Science ®Google Scholar
• Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 1999; 37: 3204–3209.
   PubMed Web of Science ®Google Scholar